The popularity of copyright’s blockbuster initially drove a surge for pharma, nevertheless recent shifts present a complicated scenario for shareholders. Lower-cost versions are eating into revenue, and ongoing litigation add further difficulty to the equation. While certain companies might still benefit Adult from complementary products, the gen